<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>275-IBRUTINIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IBRUTINIB" rxcui="1442981">
<ATC code="L01XE27" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of ibrutinib due to decrease of its hepatic metabolism by the amiodarone</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict clinical monitoring and reduction of the dose of ibrutinib to 140 mg per day during the length of time these medications are administered together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>275-IBRUTINIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IBRUTINIB" rxcui="1442981">
<ATC code="L01XE27" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of ibrutinib due to decrease of its hepatic metabolism by the diltiazem</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict clinical monitoring and reduction of the dose of ibrutinib to 140 mg/day during the length of time these medications are administered together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>275-IBRUTINIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IBRUTINIB" rxcui="1442981">
<ATC code="L01XE27" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of irutinib due to decrease of its hepatic metabolism by the verapamil</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict clinical monitoring and reduction of the dose of ibrutinib to 140mg per day during the length of time these medications are administered together. </COMMENT>
</INTERACTION>
</INTERACTIONS>
